NCT01369602View on ClinicalTrials.gov

Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Type 2 Diabetes MellitusHealthy
Interventions
DRUG

PF-04991532

single dose 300-mg

DRUG

PF-04991532

single dose 300-mg

DRUG

PF-04991532

single dose 300-mg

DRUG

PF-04991532

single dose 300-mg

Trial Locations (2)

32720

Pfizer Investigational Site, DeLand

92801

Pfizer Investigational Site, Anaheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01369602 - Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532 | Biotech Hunter | Biotech Hunter